Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of trastuzumab emtansine versus capecitabine + lapatinib in previously trastuzumab-treated HER2-positive advanced or metastatic breast cancer
2008-005713-22Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Trastuzumab emtansine with Capecitabine + lapatinib (2 arms). Primary endpoint: Progression-free survival. Started Jan 2009; status: completed.
02
Drugs
trastuzumab emtansinecapecitabinelapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-005713-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005713-22.